武汉地区123例冠心病患者CYP2C19基因多态性分布
武汉地区123例冠心病患者CYP2C19基因多态性分布
-
摘要:
目的 探讨武汉地区冠心病患者药物代谢酶CYP2C19基因多态性的分布.方法 采用基因芯片法对123例服用氯吡格雷的无血缘关系的冠心病患者进行CYP2C19基因分型, 分析其基因型及代谢表型的分布, 并与文献报道中中国汉族人群进行比较.结果 共统计发现5种基因型, 3种代谢表型;检测出快代谢型 (EM) 患者38例, 所占比例为30.9%, 检测出中间代谢型 (IM) 患者69例, 所占比例为56.1%, 检测出慢代谢型 (PM) 患者16例, 所占比例为13.0%.武汉地区冠心病患者中, CYP2C19基因代谢表型分布与文献报道无统计学意义 (P>0.05) .结论 武汉地区冠心病患者中, CYP2C19基因存在多态性, 基因频率及代谢型分布频率与国内其他地区相一致.
-
关键词:
- 冠心病 /
- CYP2C19基因多态性 /
- 代谢表型分布 /
- 氯吡格雷
Abstract:目的 探讨武汉地区冠心病患者药物代谢酶CYP2C19基因多态性的分布.方法 采用基因芯片法对123例服用氯吡格雷的无血缘关系的冠心病患者进行CYP2C19基因分型, 分析其基因型及代谢表型的分布, 并与文献报道中中国汉族人群进行比较.结果 共统计发现5种基因型, 3种代谢表型;检测出快代谢型 (EM) 患者38例, 所占比例为30.9%, 检测出中间代谢型 (IM) 患者69例, 所占比例为56.1%, 检测出慢代谢型 (PM) 患者16例, 所占比例为13.0%.武汉地区冠心病患者中, CYP2C19基因代谢表型分布与文献报道无统计学意义 (P>0.05) .结论 武汉地区冠心病患者中, CYP2C19基因存在多态性, 基因频率及代谢型分布频率与国内其他地区相一致.
-
[1] [1]NGUYEN T A, DIODATI I G, PHARAND C, et al.Resistance to clopidogrel:a review of the evidence[J].J Am Coil Cardiol, 2005, 1945 (8) :l157-1164. [2] [2]MEGA J L, CLOSE S L, WIVIOTT S D, et al.Cytochrome P-450 polymorphisms and Response to clopidogrel[J].N Engl J Med, 2009, 360 (4) :354-362. [3] [3]DICK R J, DEAR A E, BYRON K A.Clopidogrel resistance:Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis[J].Heart Lung Circ, 2011, 20 (10) :657-658. [4] [4]AUNE B, BOURBIGOT J, DEROST J, et al.Bleeding and Resistance[J].BMJ, 2009, 338:b1927. [5] [5]ANQIOLILLO D J, SURYADEVARA S.Aspirin and clopidogrel:Efficacy and resistance in diabetes mellitus[J].Best Pract Res Clin Endocrinol Metab, 2009, 23 (3) :375-388. [6]郑露, 邵建国.CYP2C19的基因多态性与临床[J].第二军医大学学报, 2008, 28 (11) :1262-1265. [7]周健, 吕虹, 康熙雄.中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测[J].中国临床药理学与治疗学, 2007, 12 (2) :208-213. [8] 尚鹏超.豫东南人群不同性别、年龄、体量指数CYP2C19基因多态性分析[J].中国基层医药, 2015, 22 (12) :3276-3279. [9] [9]HARMSZE A, WERKUM J W, BOUMAN H J, et al.Besides CYP2C19*2, the variant allele CYP2C19*3 is associated with higher onclopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation[J].Pharmacogenet Genomics, 2010, 20 (1) :18-25. [10] [10] LEE J B, LEE K A, LEE K Y.Cytochrome P4502C19polymorphismis associated with reduced clopidogrel response in cerebrovascular disease[J].Yonsei Med J.2011, 52 (5) :734-738. [11] [11]SUBRAJA K, DKHAR S A, PRIYADHARSINIR, et al.Genetic polymorphism of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population[J].Eur J Clin Pharmaco1, 2013, 69 (3) :415-422. [12] [12]HWANG S J, JEONG Y H, KIMI S, et al.The cytochrome2C19*2 and*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention[J].Thromb Res, 2011, 127 (1) :23-28. [13] [13]KIM I S, CHOI B R, JEONG Y H, et al.The CYP2C19*2and CYP2Cl9*3 polymorphisms are associated with high post treatment platelet reactivity in Asian patients with acute coronary syndrome[J].J Thromb Haemost, 2009, 7 (5) :897-899. [14] [14] SIMON T, VERSTUYFT C, MARYKRAUSE M, et al.Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med, 2009, 360 (4) :363-375. [15] [15]MEGA J L, CLOSE S L, WIVIOTT S D, et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel:relationship to pharmacokinetic, pharmacodynamic, andclinicaloutcomes[J].Circulation, 2009, 119 (19) :2553-2560. [16] [16]MEGA J L, SIMON T, COLLET J P, et al.Reduced Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated with Clopidogrel Predominantly for PCI:A Meta Analysis[J].JAMA, 2010, 304 (16) :1821-1830. [17] [17]LIANG Z Y, HAN Y L, ZHANG X L, et al.The impact of gene polymorphism and high on treatment platelet reactivity on clinical follow up:outcomes in patients with acute coronary syndrome after drug eluting stent implantation[J].Euro Intervention, 2013, 9 (3) :316-327. [18] [18]MICHAEL M, MARK F, CARMEN D M, et al.enetic variation in metabolizing enzyme and transporter genes:comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans[J].J Clin Pharmacol, 2010.50 (8) :929-940. [19] [19]JIANG D C, BAI X G, ZHANG Q X, et al.Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients:nonlinear mixed-effect modeling[J].Eur J Clin Pharmacol, 2009, 65 (12) :1187-1193. [20] CHEN L L, QIN S Y, XIE J, et al.Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of Mainland of China[J].Pharmacogenomics, 2008, 9 (6) :691-702.
计量
- 文章访问数: 2542
- HTML全文浏览量: 903
- PDF下载量: 127
- 被引次数: 0